Press Release

 

 

FOR RELEASE:

Thursday, April 28, 2015


Contact:
 Natalie Likness, Governor’s Office of Economic Development, External link opens in new tab or window605.773.3301

 

NanoBlood LLC Relocating to South Dakota

 

SIOUX FALLS, S.D. – NanoBlood LLC, based in Irvine, Calif., announced today that it is relocating to the South Dakota Technology Business Center (SDTBC) in Sioux Falls, S.D., to continue the regulatory and commercial development of its nano red blood cell as a life-saving drug in critical care and transfusion medicine.


“This is the kind of science that rewrites medical history, it’s the kind of novel drug that saves lives and it is happening right here in South Dakota,� said Gov. Dennis Daugaard. “It is my pleasure to support the translation of nano red blood cell from bench-to-bedside for unmet domestic and global medical needs.�


“The SDTBC is excited to be the new corporate location for NanoBlood, LLC,� said SDTBC vice president, Tom Stengrim. “We look forward to supporting this exciting development of a lifesaving drug for the U.S. and global market.�


“NanoBlood’s plan to use the USD Graduate Education and Applied Research (GEAR) Center’s aseptic GMP (Good Manufacturing Practice) services to fill its product for clinical trials is a great demonstration of how the USD Discovery District will help bridge the gap between bench research and industry to grow South Dakota’s economy,� said USD Discovery District president Rich Naser.


The Governor’s Office of Economic Development has funded NanoBlood through two Proof of Concept projects for further commercialization of nano red blood cell. NanoBlood is targeting FDA fast track and breakthrough designation to bring this drug to patients in need. NanoBlood plans to build a commercial manufacturing plant in Sioux Falls at the USD Research Park.


“I am very grateful and appreciative of Gov. Daugaard’s support of commercial development of nano red blood cell in South Dakota for domestic and global need in critical care and transfusion medicine,� said Carleton Hsia, chairman and CEO of NanoBlood.